Literature DB >> 10608632

Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection.

J Zimbelman1, A Palmer, J Todd.   

Abstract

CONTEXT: Animal model studies have demonstrated the failure of penicillin to cure Streptococcus pyogenes myositis and have suggested that clindamycin is a more effective treatment.
OBJECTIVE: To determine the most effective antibiotic treatment for invasive S. pyogenes infection in humans. DESIGN AND
SETTING: We conducted a retrospective review of the outcomes of all inpatients from 1983 to 1997 treated for invasive S. pyogenes infection at Children's Hospital. PATIENTS: Fifty-six children were included, 37 with initially superficial disease and 19 with deep or multiple tissue infections. MAIN OUTCOME MEASURE: Lack of progression of disease (or improvement) after at least 24 h of treatment.
RESULTS: The median number of antibiotic exposures was 3 per patient (range 1 to 6) with clindamycin predominating in 39 of 45 courses of protein synthesis-inhibiting antibiotics and beta-lactams predominating amongst the cell wall-inhibiting antibiotics in 123 of 126 of the remainder. Clindamycin was often used in combination with a beta-lactam antibiotic. Overall there was a 68% failure rate of cell wall-inhibiting antibiotics when used alone. Patients with deep infection were more likely to have a favorable outcome if initial treatment included a protein synthesis-inhibiting antibiotic as compared with exclusive treatment with cell wall-inhibiting antibiotics (83% vs. 14%, P = 0.006) with a similar trend in those with superficial disease (83% vs. 48%, P = 0.07). For those children initially treated with cell wall-inhibiting antibiotics alone, surgical drainage or debridement increased the probability of favorable outcome in patients with superficial disease (100% vs. 41%, P = 0.04) with a similar trend in a smaller number of deep infections (100% vs. 0%, P = 0.14).
CONCLUSIONS: This retrospective study suggests that clindamycin in combination with a beta-lactam antibiotic (with surgery if indicated) might be the most effective treatment for invasive S. pyogenes infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608632     DOI: 10.1097/00006454-199912000-00014

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  58 in total

Review 1.  Evaluation and Management of Necrotizing Soft Tissue Infections.

Authors:  Stephanie L Bonne; Sameer S Kadri
Journal:  Infect Dis Clin North Am       Date:  2017-09       Impact factor: 5.982

2.  Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system.

Authors:  Arnold Louie; Brian D Vanscoy; Henry S Heine; Weiguo Liu; Terry Abshire; Kari Holman; Robert Kulawy; David L Brown; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  Molecular diagnosis of necrotizing fasciitis by 16S rRNA gene sequencing and superantigen gene detection.

Authors:  Kenneth L Muldrew; Jean F Simpson; Charles W Stratton; Yi-Wei Tang
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

4.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

5.  Recent advances in the treatment of necrotizing fasciitis.

Authors:  Marina S Morgan
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

6.  Pediatric anthrax clinical management.

Authors:  John S Bradley; Georgina Peacock; Steven E Krug; William A Bower; Amanda C Cohn; Dana Meaney-Delman; Andrew T Pavia
Journal:  Pediatrics       Date:  2014-05       Impact factor: 7.124

7.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

8.  Group G streptococcal sepsis, septic arthritis and myositis in a patient with severe oral ulcerations.

Authors:  Wu Deng; Laurie Farricielli
Journal:  BMJ Case Rep       Date:  2014-01-27

9.  Necrotizing fasciitis resulting from human bites: A report of two cases of disease caused by group A streptococcus.

Authors:  Christopher A Sikora; Jack Spielman; Kerry Macdonald; Gregory J Tyrrell; John M Embil
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

10.  Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004.

Authors:  Bogdan Luca-Harari; Kim Ekelund; Mark van der Linden; Margit Staum-Kaltoft; Anette M Hammerum; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.